Supreme Court Constitutes Expert Committee to Curb Unethical Drug Marketing

Supreme Court Tackles Unethical Drug Marketing Practices

The Supreme Court of India took a serious stance on Tuesday, October 8, 2026, against pharmaceutical companies influencing physicians through expensive gifts, financial benefits, foreign trips, and other inducements to promote their drugs. The apex court has directed the central government to constitute a three-member expert committee to conduct a comprehensive review of such unethical marketing practices.

This committee will examine the effectiveness of existing regulations, monitoring mechanisms, and provisions for action against violations, and will submit its recommendations to the government. The next hearing in the case is scheduled for January 29, 2027. This directive is considered a significant step towards fostering greater transparency, accountability, and patient-centricity in the relationship between the pharmaceutical industry and the medical profession.

The order was issued by a bench comprising Justices Vikram Nath and Sandeep Mehta, hearing a petition filed by the Federation of Medical and Sales Representatives Association of India (FMRAI). The petition sought effective control over transactions between drug companies and doctors that could potentially influence medical decisions regarding drug selection.

Expert Committee's Mandate and Responsibilities

The expert committee, once constituted, will be expected to submit its recommendations within two months of its first meeting. The court has granted the committee the liberty to hear suggestions and objections from relevant parties and to seek assistance from technical and medical experts if necessary.

Following the committee's report, the central government will need to consider its recommendations and make an appropriate and reasoned decision. The court's objective is not merely to increase the number of regulations but to ensure their actual and effective enforcement. Given that medicines are directly linked to citizens' health, lives, and financial security, a lack of accountability in this sector cannot be dismissed as a mere commercial dispute.

Concerns Over Pharmaceutical Marketing Practices

Allegations of pharmaceutical companies offering doctors expensive gifts, electronic gadgets, hospitality, entertainment, sponsored travel under the guise of conferences, and other financial benefits for marketing purposes have been persistent. Such inducements can create indirect pressure to prescribe specific brands of drugs.

The critical concern is whether the decision to prescribe a drug is based on patient need, its utility, safety, and quality, or on commercial promotion and profit. However, it is also important not to immediately deem every doctor or company guilty based on such allegations; investigations and actions must be evidence-based.

The problem escalates when the commercial preference for a drug overrides its utility, safety, quality, and the genuine needs of the patient. A doctor should make treatment decisions considering the patient's illness, age, other medications, potential side effects, and financial capacity. If the decision to prescribe is influenced by a gift or financial benefit, it not only undermines medical independence but also erodes patient trust.

Dolo-650 Case and the Need for Regulation

In this context, the case involving the drug Dolo-650 also surfaced, highlighting the need for an independent investigation into drug company promotional expenses and their potential impact on benefits given to doctors. In August 2022, the petitioners alleged that the company manufacturing this drug had distributed gifts worth approximately ₹1,000 crore to encourage doctors to prescribe it. This allegation was part of the arguments presented in court and should not be construed as a final judicial finding or proven offense.

This instance underscored the lack of transparency and accountability in the pharmaceutical industry. While research, medical training, dissemination of new drug information, and scientific conferences have legitimate roles, a clear line must be drawn between these vital activities and marketing practices that serve personal gain. Transparent regulations can help maintain useful scientific collaboration while effectively curbing undue incentives.

Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024

The central government has implemented the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024, to regulate the marketing activities of pharmaceutical companies. This code, released on March 12, 2024, sets ethical standards for interactions between doctors and drug companies. It prohibits companies from offering gifts, monetary benefits, and undue hospitality to doctors and their families.

The code also emphasizes company accountability, self-declaration of compliance, and disclosure of expenses related to medical education events. However, the fundamental question remains: how quickly are violations of this code acted upon, and how effectively is accountability ensured for non-compliant companies? The current system involves ethics committees at the company level investigating complaints, with an appellate mechanism at the Department of Pharmaceuticals.

Yet, questions persist regarding the gap between voluntary compliance, the industry's self-regulatory mechanisms, and binding government control. It is in this regard that the Supreme Court has called for a consideration of the adequacy of the existing system and the need to make it more effective.

Potential Impact and the Way Forward

If the expert committee recommends a stronger legal basis for regulations, the government will need to decide who will investigate violations, how penalties will be determined, and what simplified procedures will be available for complainants to seek redressal. Ensuring a fair opportunity for the concerned companies and doctors to present their case will also be mandatory.

The potential impact of unethical marketing extends beyond medical decisions. If a patient is prescribed an expensive branded drug when a less expensive alternative with the same active pharmaceutical ingredient, appropriate dosage, and quality is available, their treatment costs can increase unnecessarily. However, it is also incorrect to consider every expensive drug as unnecessary and every cheaper drug as equally appropriate; drug selection must be based on quality, efficacy, safety, and the patient's specific needs.

A report published in October 2026 cited an example of a cancer drug presented before the court with a Maximum Retail Price (MRP) of approximately ₹27,000, while its supply to retailers was reportedly between ₹2,700 and ₹3,000, a difference of about nine to ten times. Although this is an example related to a specific drug and not an average price difference across the entire market, it raises critical questions about drug pricing, transparency, and the financial capacity of patients.

In a country like India, where many families still bear treatment costs out-of-pocket, purchasing unnecessarily expensive medicines can strain their household budgets. Therefore, doctors' independence, fair drug pricing, and patient access to information about various options are all interconnected issues. Patients should be informed about lower-cost, quality alternatives whenever medically appropriate.

Antimicrobial Resistance (AMR) and Drug Promotion

Another significant aspect of this issue is the serious problem of Antimicrobial Resistance (AMR). When microorganisms like bacteria develop the ability to evade the effects of drugs, treating infections can become extremely difficult. The overuse of antibiotics, incorrect drug selection, inappropriate dosages, and non-adherence to treatment instructions are major factors contributing to this problem.

While the inappropriate use of antibiotics cannot be directly attributed solely to one marketing practice, as there are many other reasons, including self-medication without proper medical advice, misdiagnosis of infections, limited access to healthcare services, and deficiencies in infection control...